دورية أكاديمية
Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
| العنوان: | Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection. |
|---|---|
| المؤلفون: | Phaisal W; Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Albitar O; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia., Chariyavilaskul P; Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Jantarabenjakul W; Center of Excellence for Paediatric Infectious Diseases and Vaccines, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Thai Red Cross Emerging Infectious Diseases Clinical Centre, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.; Division of Infectious Diseases, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Wacharachaisurapol N; Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.; Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Ghadzi SMS; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia., Zainal H; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia., Harun SN; School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia. |
| المصدر: | The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Jun 03; Vol. 79 (6), pp. 1270-1278. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 7513617 Publication Model: Print Cited Medium: Internet ISSN: 1460-2091 (Electronic) Linking ISSN: 03057453 NLM ISO Abbreviation: J Antimicrob Chemother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 1997- : London : Oxford University Press Original Publication: London, New York, Academic Press. |
| مواضيع طبية MeSH: | Rifampin*/pharmacokinetics , Rifampin*/analogs & derivatives , Rifampin*/administration & dosage , Rifampin*/therapeutic use , Isoniazid*/pharmacokinetics , Isoniazid*/urine , Isoniazid*/administration & dosage , Isoniazid*/therapeutic use , Antitubercular Agents*/pharmacokinetics , Antitubercular Agents*/administration & dosage , Antitubercular Agents*/therapeutic use , Arylamine N-Acetyltransferase*/genetics , Tuberculosis*/drug therapy, Humans ; Male ; Female ; Child ; Child, Preschool ; Liver-Specific Organic Anion Transporter 1/genetics ; Genotype ; Polymorphism, Single Nucleotide ; ATP Binding Cassette Transporter, Subfamily B/genetics ; Adolescent ; Infant |
| مستخلص: | Objectives: Twelve weekly doses of rifapentine and isoniazid (3HP regimen) are recommended for TB preventive therapy in children with TB infection. However, they present with variability in the pharmacokinetic profiles. The current study aimed to develop a pharmacokinetic model of rifapentine and isoniazid in 12 children with TB infection using NONMEM. Methods: Ninety plasma and 41 urine samples were collected at Week 4 of treatment. Drug concentrations were measured using a validated HPLC-UV method. MassARRAY® SNP genotyping was used to investigate genetic factors, including P-glycoprotein (ABCB1), solute carrier organic anion transporter B1 (SLCO1B1), arylacetamide deacetylase (AADAC) and N-acetyl transferase (NAT2). Clinically relevant covariates were also analysed. Results: A two-compartment model for isoniazid and a one-compartment model for rifapentine with transit compartment absorption and first-order elimination were the best models for describing plasma and urine data. The estimated (relative standard error, RSE) of isoniazid non-renal clearance was 3.52 L·h-1 (23.1%), 2.91 L·h-1 (19.6%), and 2.58 L·h-1 (20.0%) in NAT2 rapid, intermediate and slow acetylators. A significant proportion of the unchanged isoniazid was cleared renally (2.7 L·h-1; 8.0%), while the unchanged rifapentine was cleared primarily through non-renal routes (0.681 L·h-1; 3.6%). Participants with the ABCB1 mutant allele had lower bioavailability of rifapentine, while food prolonged the mean transit time of isoniazid. Conclusions: ABCB1 mutant allele carriers may require higher rifapentine doses; however, this must be confirmed in larger trials. Food did not affect overall exposure to isoniazid and only delayed absorption time. (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.) |
| معلومات مُعتمدة: | HEA663000032 Thailand Science Research and Innovation Fund Chulalongkorn University; RA-MF-32/65 Ratchadapisek Somphot Fund, Faculty of Medicine, Chulalongkorn University; HSRI 65-019 Health Systems Research Institute |
| المشرفين على المادة: | VJT6J7R4TR (Rifampin) V83O1VOZ8L (Isoniazid) XJM390A33U (rifapentine) 0 (Antitubercular Agents) EC 2.3.1.5 (Arylamine N-Acetyltransferase) EC 2.3.1.5 (NAT2 protein, human) 0 (Liver-Specific Organic Anion Transporter 1) 0 (SLCO1B1 protein, human) 0 (ATP Binding Cassette Transporter, Subfamily B) 0 (ABCB1 protein, human) |
| تواريخ الأحداث: | Date Created: 20240425 Date Completed: 20240602 Latest Revision: 20240602 |
| رمز التحديث: | 20240603 |
| DOI: | 10.1093/jac/dkae059 |
| PMID: | 38661209 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1460-2091 |
|---|---|
| DOI: | 10.1093/jac/dkae059 |